Education
ASCO 2020: Personalised treatment strategies in melanoma could reduce toxicity burden from immunotherapy without compromising benefits
3 Sep, 2020Treatment of melanoma has switched gears after immune checkpoint inhibitor (ICI) therapies were first introduced in 2011. Currently, the combination of anti-programmed cell death protein 1 (PD-1) inhibitor nivolumab (Opdivo) and anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4) inhibitor ipilimumab (Yervoy) is the most aggressive treatment regimen available for advanced metastatic melanoma. This combination demonstrated a 52% 5-year survival rate in the Phase III CheckMate-062 study, establishing it as a standard of care in frontline treatment of melanoma.
Read more here: https://www.clinicaltrialsarena.com/comment/asco-2020-melanoma/